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Abstract
Multidrug resistance (MDR) is a major cause of failure in cancer chemotherapy. Tocopheryl
polyethylene glycol 1000 succinate (TPGS) has been extensively explored for the treatment of
MDR in cancer because of its ability to inhibit P-glycoprotein. Here, we have established
multifunctional nanoparticles (MFNPs) using a single-molecule modification of TPGS, which can
deliver a hydrophobic drug, paclitaxel (PTX), and a hydrophilic drug, fluorouracil (5-FU), and
overcome MDR in cancer. Our data indicated that, when delivered into a PTX-resistant cell line
using MFNPs, the combination of PTX and 5-FU was more cytotoxic than each agent
individually.
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The development of multidrug resistance (MDR) to a variety of chemotherapeutic agents is
one of the major challenges to effective cancer treatment.1 Of the various mechanisms
mediating MDR, resistance conferred by the P-glycoprotein (P-gp) transporter is the best
characterized and is of considerable clinical importance. P-gp functions by increasing the
eflux of drugs out of the cell against a concentration gradient, thereby decreasing
intracellular levels of the drugs below their level of effectiveness, a phenomenon that leads
to drug resistance.2 An efficient strategy in overcoming MDR using highly selective P-gp
inhibitors has become attractive. For example, tocopheryl polyethylene glycol 1000
succinate (TPGS) has been extensively investigated for use as an inhibitor of P-gp.3–5
Similarly, the development of nanocarriers of combined drugs that exhibit a high loading
efficiency presents a significant challenge, particularly when the drugs being codelivered are
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hydrophobic and hydrophilic. The nanocarriers are designed to deliver combined drugs to
the target cells; each individual drug resides within the signaling pathways in the cancer
cells, causing synergistic effects. However, if the drugs are high-affinity substrates for P-gp
[e.g., paclitaxel (PTX)], an additional agent, specifically a P-gp inhibitor, should be
codelivered in the nanocarriers. Here, we demonstrate that multifunctional nano-particles
(MFNPs) could be created through a single-molecule modification of TPGS [i.e.,
conjugation of fluorouracil (5-FU) to TPGS]. As the 5-FU–TPGS conjugate and PTX are
assembled into MFNPs, the segment of TPGS serves several functions: (1) carrying the
hydrophilic drug (5-FU), (2) delivering a hydrophobic drug (PTX), (3) inhibiting P-gp to
reverse MDR, and (4) stabilizing the MFNP.
Various derivatives of 5-fluorouracil (5-FU) have been used as antitumor agents in recent
years. For example, N-acylox-ymethyl-5-fluorouracil exhibits strong antitumor activity.6
Therefore, we have conjugated TPGS with N-hydroxymethyl-5-fluorouracil via an ester
bond to produce a 5-fluorouracil–TPGS conjugate (5-FU–TPGS), which contains an
acyloxy-methyl group at position N-1. To create this conjugate, succinoylated TPGS (1) was
synthesized according to the methods described by S.-S. Feng.7 During this process, 5-FU
was treated with formalin to generate 1,3-dihydroxymethyl-5-fluorouracil (2). Next,
succinoylated TPGS (1, 1.60 g, 1 mmol), 1,3-dihydroxymethyl-5-fluorouracil (2, 0.23 g, 1.2
mmol), and DCC (0.25 g, 1.2 mmol) in the presence of a catalytic amount of DMAP in
anhydrous CH3CN were stirred at room temperature under a nitrogen atmosphere for 24 h.
The resulting mixture was filtered to remove N,N-dicyclohexylurea (DCU) and evaporated
under reduced pressure until it was dry. The residue was purified using silica-gel column
chromatograpy, eluting with a chloroform/methanol solution with increasing methanol
content. After the solvent was removed in vacuo, a 5-FU–TPGS conjugate was obtained,
appearing as a waxy white solid. The chemical structure of the synthesized 5-FU–TPGS
conjugate was confirmed by 1H NMR (Figure S1 of the Supporting Information) and mass
(Figure S2 of the Supporting Information) spectra.
Like other nonionic surfactants, TPGS is composed of a hydrophobic tail (vitamin E) and a
hydrophilic head (PEG1000). Because the 5-FU–TPGS conjugate was synthesized by
coupling 5-FU to the hydrophilic headgroup, PEG1000, the hydrophobicity of vitamin E
remains intact. We expected that PTX-loaded MFNPs (diagramed in Figure 1) could be
assembled through a hydrophobic interaction between PTX and the hydrophobic tail of 5-
FU–TPGS, which would be stabilized by the hydrophilic portion of the particle.
Before assembling the MFNPs, we characterized 5-FU–TPGS to determine its ability to
inhibit P-gp and antitumor activity. Rhodamine 123 (RH123), a fluorescent dye, is an
established substrate of P-gp, which has been commonly used to examine the ability of
inhibitors to block P-gp-mediated transport.8 Previous studies have shown that H460/TaxR
cells derived from human, non-small cell lung cancer overexpress P-gp and are resistant to
PTX.9 Therefore, this cell line was used to demonstrate the effects of 5-FU–TPGS on P-gp
inhibition. Through the quantification of the uptake of RH123, we determined if the
synthesized conjugate maintained the ability to inhibit P-gp. Low levels of uptake of RH123
by H460/TaxR cells and an increase of >10-fold in uptake when the cells were treated with
15 μM TPGS or 5-FU–TPGS were observed (Figure 2a). This result confirms that the 5-
FU–TPGS conjugate exhibits a P-gp-inhibitory ability similar to that of TPGS in an MDR
cell line.
Similarly, the upregulation of protein 53 (p53) by 5-FU is a critical component of the drug
that should be maintained by the MFNPs. p53 is a well-established tumor suppressor that is
upregulated by 5-FU.10,11 Theoretically, the prodrug of 5-FU–TPGS should alter p53
transcriptional and translational regulation as efficiently as 5-FU, leading to the upregulation
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of the protein. The expression of p53 in response to treatments was clearly upregulated by
both 5-FU–TPGS and free 5-FU in both KB-3-1 (human epidermoid carcinoma cells, a 5-
FU-sensitive cell line) and H460/TaxR cells (Figure 2b). Additionally, the cytotoxicity of 5-
FU–TPGS was examined to confirm its ability to kill cancer cells. Using MTS in KB-3-1
cells, 5-FU–TPGS was demonstrated to possess the same anticancer efficacy as free 5-FU
(data not shown).
Previously published methods of preparation were used to synthesize MFNPs.12 PTX and 5-
FU–TPGS were dissolved in chloroform and coprecipitated by evaporation of the
chloroform with a steady flow of nitrogen gas. A trace amount of chloroform was removed
by keeping the precipitates under a vacuum in a desiccator for 2–4 h. After being hydrated
and vortexed in water for 30 min, suspensions were sonicated for 15 min in a bath-type
sonicator (output of 80 kC, 80 W) to form MFNPs. As shown in Figure 3a, the final MFNPs
with a PTX:5-FU–TPGS ratio of 1:6 (w:w) exhibit an average hydrodynamic diameter of
105 nm and a polydispersity index (PDI) of 0.142 (Figure 3a). The size and morphology of
MFNPs were also determined using a transmission electron microscope; results illustrated
that the NPs were rod-shaped (Figure 3b). The release of 5-FU from the MDNPs was
confirmed using high-performance liquid chromatography. When the MFNPs were
incubated at 37 °C in PBS for 12, 24, and 36 h, 16.4, 23.4, and 34.2% of released 5-FU were
detected, respectively. It has been reported that 5-FU was released from its prodrug using
CH2O as a linker after hydrolysis (two steps).12 As the 5-FU is conjugated to TPGS using
the CH2O linker, the release of 5-FU may also occur through the two-step hydrolysis
process.
PTX exerts cytotoxic effects by binding tubulin, promoting the assembly of tubulin, and
stabilizing microtubules, ultimately leading to cell death by apoptosis. Therefore, we
measured the levels of β-tubulin in KB-3-1 and NCI/ADR-RES (MDR human breast cancer)
cell lines after these cells were treated with PTX delivered in different formulations.
Western blot results showed that β-tubulin assembly was enhanced in KB-3-1 cells by PTX
treatments, including PTX alone, PTX/TPGS nanoparticles (PTX/TPGS NPs), and MFNPs
(Figure 4a). Importantly, MDR cell lines of NCI/ADR-RES that were treated with both
PTX/TPGS NPs and MFNPs displayed enhanced assembly of β-tubulin, but cells treated
with PTX alone did not. These results suggest (1) 5-FU–TPGS encapsulated in MFNPs does
not interfere with the PTX-mediated binding of β-tubulin and (2) 5-FU–TPGS can
efficiently inhibit the ability of P-gp to pump the released PTX out of cells.
Next, the ability of MFNPs (5 μM PTX) to overcome MDR and achieve antitumor effects in
H460/TaxR cells was evaluated. PTX/F127 (Pluronic F-127) NPs developed in our lab were
selected as a control because of the similarities in geometry to that of the MFNPs and the
fact that F127 is an ineffective inhibitor of P-gp.13 As shown in Figure 4b, PTX alone and
PTX/F127 NPs [1:5 (w:w) PTX:F127 ratio] did not induce significant toxicity. However,
compared to PTX alone, 5-FU and PTX/TPGS NPs exhibited 79% (p < 0.05) and 55% (p <
0.01) toxicity to cell viability, respectively. On the other hand, the cytotoxicity was
increased to 27% viability in cells treated with MFNPs (compared to PTX/TPGS NPs, p <
0.05), eluding to the synergistic effect of the combined delivery of PTX with 5-FU.
We assumed that the level of cellular accumulation of PTX would increase as TPGS was
released during the hydrolysis of 5-FU–TPGS in the acidic environment of the endosomal
compartment. The inhibition of P-gp prevents the removal of PTX from cells, causing an
increase in the concentration of the drug. This pattern was illustrated through the use of 3H-
labeled PTX, which was added to the preparations of PTX/5-FU–TPGS MFNPs, PTX/TPGS
NPs, and PTX (in DMSO). After incubation with the 3H-labeled samples for 5 h at 37 °C,
the cells were harvested with trypsin-EDTA, washed with PBS to ensure the removal of free
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PTX or NPs, and lysed with Triton X-100. The radioactivity of 3H-labeled PTX was
measured using a liquid scintillation analyzer. The cellular accumulation of PTX was
significantly enhanced in the cells treated with either MFNPs or PTX/TPGS NPs compared
with free PTX or PTX/F127 NPs (Figure 4c). The liquid scintillation analyzer results also
support our conclusion that 5-FU–TPGS can inhibit P-gp activity as efficiently as TPGS,
which is consistent with the data illustrating the uptake of RH123 (Figure 2a).
Currently, all nanoparticles that have been approved by the U.S. Food and Drug
Administration for cancer therapy or in advanced stages of clinical testing rely on the
enhanced permeability and retention (EPR) mechanism.14 The EPR mechanism allows
passive targeting through the disorganized and leaky vasculature, as well as the reduced
lymphatic drainage of tumor tissues. The newly developed MFNPs containing both
hydrophobic PTX and covalently conjugated hydrophilic 5-FU, with a particle size of ~100
nm, are also able to accumulate in tumor tissues through the EPR effect. The MFNPs
reported here can be further improved through the addition of a tumor-targeting ligand that
selectively targets MDR cancer cells without affecting the health of other cells throughout
the body.
In conclusion, we have established MFNPs that are able to deliver a hydrophobic drug, PTX,
and a hydrophilic drug, 5-FU, for the purpose of overcoming MDR in cancer. MFNPs are
now being actively investigated and highlight the promising future of nanotechnology.15,16
Our data show for the first time that MFNPs with a high efficiency of drug loading can be
formulated through a single-molecule modification, i.e., conjugation of 5-FU to TPGS. The
yield of loading of the combined drugs in MFNPs can be as high as 20% (PTX with 5FU/
excipient), demonstrating the high drug carrying capacity of the NPs. Combined drugs have
been routinely applied as cotherapies to achieve optimal therapeutic benefits. The new
MFNPs codelivering PTX with 5-FU are ideally suited to achieve maximal therapeutic
activity, as each drug simultaneously targets different mechanisms and/or different signaling
pathways in cancer killing, particularly in MDR cancer cells.
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Schematic diagram of the assembly of MFNP with PTX and 5-FU–TPGS.
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Functional assay of the 5-FU–TPGS conjugate. (a) Effect of the 5-FU–TPGS conjugate on
P-gp inhibition determined by the flow-cytometric assessment of the uptake of rhodamine
123 (RH123) in H460/TaxR cells. (b) Western blot for the detection of p53 expression in
response to 5-FU and 5-FU–TPGS in KB-3-1 and H460/TaxR cells.
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Characterization of MFNPs. (a) Particle size distribution of MFNPs, measured using
dynamic light scattering. (b) Transmission electron microscopy imaging of MFNPs. The
PTX:5-FU–TPGS ratio in MFNPs was 1:6 (w:w).
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Bioactivity assay of MFNPs. (a) Enhanced tubulin assembly detected by Western blot
analysis in KB-3-1 and NCI/ADR-RES cells (the MDR cell line, H460/TaxR, was not used
here because it was induced by PTX, resulting in a high background of β-tubulin) after these
cells were treated with PTX, PTX/TPGS NPs, or MFNPs. All formulations were normalized
to equivalent levels of PTX (5 μM), and PTX/TPGS NPs contained the same molar weight
of TPGS as MFNPs loaded with 5-FU–TPGS. (b) Cytotoxicity assay in H460/TaxR cells (n
= 6). One asterisk indicates a significant difference compared to PTX (p < 0.05). Two
asterisks indicate a highly significant difference compared to PTX (p < 0.01). A number sign
indicates a significant difference compared to PTX/TPGS NPs (p < 0.05). (c) Cellular
uptake of [3H]PTX in different formulations. Two asterisks indicate a highly significant
difference compared to PTX (p < 0.01).
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